Edgewise Therapeutics, Inc.
EWTX
$14.60
$0.302.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.12M | -40.80M | -39.66M | -34.13M | -31.50M |
| Total Depreciation and Amortization | 567.00K | 554.00K | 629.00K | 602.00K | 534.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.53M | 7.14M | 5.14M | 3.64M | 1.67M |
| Change in Net Operating Assets | -2.56M | -4.76M | 6.94M | 2.51M | 3.19M |
| Cash from Operations | -32.58M | -37.87M | -26.96M | -27.37M | -26.10M |
| Capital Expenditure | -50.00K | -44.00K | -274.00K | -520.00K | -221.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -162.12M | 43.94M | 21.20M | 25.88M | 37.59M |
| Cash from Investing | -162.17M | 43.90M | 20.92M | 25.36M | 37.37M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 188.19M | 2.26M | 2.90M | 3.55M | 2.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 38.00K | -38.00K | 0.00 | -214.00K | -48.00K |
| Cash from Financing | 188.23M | 2.22M | 2.90M | 3.33M | 1.95M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.52M | 8.26M | -3.14M | 1.32M | 13.22M |